提醒:代购产品,无质量问题不接受退换货,下单前请仔细核对信息。下单后请及时联系客服 核对商品价格,订单生效后再付款。
Olink/C-type lectin domain family 4 member G (CLEC4G)/Q6UXB4
价格:

自营商城

解放采购

正品保障

及时交付

厂家直采

一站服务

货号:
品牌:
会员服务:
尊享会员价
贵宾专线
运费优惠
闪电退款
福利优惠
上门换新
友情提示
以上价格仅为参考,请联系客服询价。
免费咨询热线
4000-520-616
产品说明
C-type lectin domain family 4 member G (CLEC4G)Links to databasesUniprot Q6UXB4Binds mannose, N-acetylglucosamine (GlcNAc) and fucose, but not galactose, in a Ca(2+)-dependent manner, in vitro. (Microbial infection) Acts as a receptor for Japanese encephalitis virus (PubMed:24623090). Acts as a receptor for ebolavirus (PubMed:16051304). Acts as a receptor for SARS coronavirus/SARS-CoV (PubMed:16051304). Acts as a receptor for lassa virus and Lymphocytic choriomeningitis virus glycoprotein (PubMed:22156524, PubMed:22673088).Sample typeRecommended sample types are EDTA plasma and serum. A range of additional sample types are compatible with the technology (PEA), including citrate plasma, heparin plasma, cerebrospinal fluid, (CSF), tissue and cell lysates, fine needle biopsis, microdialysis fluid, cell culture media, dried blood spots, synovial fluid, saliva, plaque extract and microvesicles. Please note that protein expression levels are expected to vary in different sample types. Certain assays are differentially affected by interfering substances such as hemolysate. Download any of our Data Validation documents or contact support@olink.com for more information. Analytical Measuring RangePlease note: the technical data reported below refers to the measured value in the in vitro validation assays. The calibrator curve below shows the performance of the assay with the estimated sensitivity and dynamic range parameters indicated. These curves are generated during the assay validation process using recombinant antigens. Please note that when analyzing biological samples the data generated will be given in the form of relative quantification (NPX values) and cannot be converted to absolute protein concentrations. For more info about NPX measurements, please visit our FAQ page (https://www.olink.com/question/what-is-npx).LOD (pg/mL) 0.9LLOQ (pg/mL) 0.95ULOQ (pg/mL) 31250Hook (pg/mL)62500Range (logs) 4.5Calibrator curve for validation data (generated in multiplex)PrecisionWithin run precision Coefficient of Variation (CV) 9%Between run precision Coefficient of Variation (CV)19%Precision (repeatability) is calculated from linearized NPX values over LOD.Biomarker Validation DataAdditional validation data, as well as a more detailed description of how the Olink panels are quality controlled can be found in our Data Validation documents. To download or to learn more go to the Data Validation page.View all Immune Response panel biomarkers >View all biomarkers >

Olink Proteomics is a Swedish company dedicated to innovation, quality, rigor and transparency, providing outstanding products and services for human protein biomarker discovery. Our groundbreaking Olink panels for precision proteomics help scientists make research decisions more quickly and confidently through robust, multiplex biomarker analysis. Our high quality multiplex immunoassay panels help bring new insights into disease processes, improve disease detection, and contribute to a better understanding of biology.

Based on the pioneering research of Professor Ulf Landegren and his group at Uppsala University, Sweden, Olink was founded in 2004, The company has a successful history of developing molecular technologies, with a broad IP portfolio. Many of these have been commercialized through out-licensing to industry leading partners such as Affymetrix, Life Technologies, and through the spin-out companies Qlinea and Halo Genomics (now part of Agilent). Olink sold its highly successful Duolink product line for in situ detection of proteins to Sigma-Aldrich in 2015.

Following a company reorganization in April, 2016, Olink Proteomics is focusing entirely on developing and expanding its platform of high-multiplex immunoassay panels for protein biomarker discovery, while Olink Bioscience is responsible for the development and commercialization of the remaining extensive and expanding, diverse Olink IP portfolio. (You can read the press release here).